Rosenzweig-Lipson S, Bergman J
Harvard University, Department of Psychology, Cambridge, Massachusetts.
J Pharmacol Exp Ther. 1993 Nov;267(2):765-75.
The discriminative-stimulus effects of the selective dopamine D1 agonist 6-chloro-7,8-dihydroxy-1-phenyl-2,3,4,5-tetrahydro-[1H]-3-benzazepine (SKF 81297) were investigated in squirrel monkeys trained to discriminate i.v. injections of SKF 81297 from saline in a two-lever drug-discrimination procedure. SKF 81297 produced dose-related increases in responding on the SKF 81297-associated lever with full substitution occurring at the training dose in all monkeys. Pretreatment with the selective D1 antagonist(-)-trans-6-7,7a,8,9,13b-hexahydro-3-chloro-2-hydroxy-N- methyl-5H- benzo(d)naphtho-(2,1-b)azepine 2-(SCH 39166) and the D1 partial agonist 7,8-dihydroxy-3-methyl-1-phenyl-2,3,4,5-tetrahydro-[1H]-3-benzazepine (SKF 75670) produced rightward shifts of the dose-effect curve for the discriminative-stimulus effects of SKF 81297, indicative of surmountable antagonism. Pretreatment with the selective D2 antagonist eticlopride, however, did not systematically alter the discriminative-stimulus effects of SKF 81297. Stereoselectivity was evident in the discriminative-stimulus effects of the enantiomers of the structurally related D1 agonist 3-allyl-6-bromo-7,8-dihydroxy-1-phenyl-2,3,4,5-tetrahydro-[1H]-3-benz azepin e (6-Br-APB), with the R-, but not the S-enantiomer, producing dose-related increases in responding on the SKF 81297-associated lever and full substitution in all monkeys. Another selective D1 agonist 6-chloro-7,8-dihydroxy-1-phenyl-2,3,4,5-tetrahydro-3-allyl-[1H]-3- benzazepine (SKF 82958) and the nonselective D1/D2 agonists (-)apomorphine and (-)4,6,6a,7,8,12b-hexahydro-7 methyl-indolo[4,3-ab]phenanthridine (CY 208-243), also engendered dose-related increases in SKF 81297-appropriate responding with full substitution occurring in one-half of the monkeys studied. The D2 agonists, (+)-4-propyl-9-hydroxynaphthoxazine and quinpirole, engendered dose-related increases in SKF 81297-appropriate responding but did not substitute fully in any monkey studied. Other dopaminergic drugs, including the D1 partial agonists SKF 75670 and R(+)-7,8-dihydroxy-1-phenyl-2,3,4,5-tetrahydro-[1H]-3- benzazepine (R-SKF 38393), and the indirect dopamine agonists, cocaine, d-amphetamine and 1-(2-[bis(4-fluorophenyl)methoxy]ethyl)-4-(3-phenylpropyl)piperazine (GBR 12909), did not substitute fully for SKF 81297 in any monkey studied. These results suggest that agonist actions at the D1 subtype of dopamine receptor are prominently involved in the discriminative-stimulus effects of SKF 81297.
在松鼠猴中研究了选择性多巴胺D1激动剂6-氯-7,8-二羟基-1-苯基-2,3,4,5-四氢-[1H]-3-苯并氮杂卓(SKF 81297)的辨别刺激效应。这些松鼠猴通过双杠杆药物辨别程序接受训练,以区分静脉注射SKF 81297和生理盐水。SKF 81297使与SKF 81297相关的杠杆上的反应呈剂量依赖性增加,所有猴子在训练剂量时均出现完全替代。用选择性D1拮抗剂(-)-反式-6-7,7a,8,9,13b-六氢-3-氯-2-羟基-N-甲基-5H-苯并(d)萘并(2,1-b)氮杂卓2-(SCH 39166)和D1部分激动剂7,8-二羟基-3-甲基-1-苯基-2,3,4,5-四氢-[1H]-3-苯并氮杂卓(SKF 75670)预处理后,SKF 81297辨别刺激效应的剂量-效应曲线向右移动,表明存在可克服的拮抗作用。然而,用选择性D2拮抗剂依替必利预处理并没有系统地改变SKF 81297的辨别刺激效应。在结构相关的D1激动剂3-烯丙基-6-溴-7,8-二羟基-1-苯基-2,3,4,5-四氢-[1H]-3-苯并氮杂卓(6-Br-APB)对映体的辨别刺激效应中,立体选择性明显,R-对映体(而非S-对映体)使与SKF 81297相关的杠杆上的反应呈剂量依赖性增加,且在所有猴子中均出现完全替代。另一种选择性D1激动剂6-氯-7,8-二羟基-1-苯基-2,3,4,5-四氢-3-烯丙基-[1H]-3-苯并氮杂卓(SKF 82958)以及非选择性D1/D2激动剂(-)阿扑吗啡和(-)4,6,6a,7,8,12b-六氢-7-甲基-吲哚并[4,3-ab]菲啶(CY 208-243)也使与SKF 81297相符的反应呈剂量依赖性增加,在所研究的猴子中有一半出现完全替代。D2激动剂(+)-4-丙基-9-羟基萘氧嗪和喹吡罗使与SKF 81297相符的反应呈剂量依赖性增加,但在所研究的任何猴子中均未完全替代。其他多巴胺能药物,包括D1部分激动剂SKF 75670和R(+)-7,8-二羟基-1-苯基-2,3,4,5-四氢-[1H]-3-苯并氮杂卓(R-SKF 38393),以及间接多巴胺激动剂可卡因、d-苯丙胺和1-(2-[双(4-氟苯基)甲氧基]乙基)-4-(3-苯基丙基)哌嗪(GBR 12909),在所研究的任何猴子中均未完全替代SKF 81297。这些结果表明,多巴胺受体D1亚型的激动剂作用在SKF 81297的辨别刺激效应中起主要作用。